Tyrosine kinase microsphers

• US 20050244477A1
• Filed: 04/29/2005
• Published: 11/03/2005
• Est. Priority Date: 04/30/2004
• Status: Active Grant

• Current Assignee: Allergan Incorporated (Abbvie Incorporated)
• Original Assignee: Allergan Incorporated (Abbvie Incorporated)
• Inventors: Rossi, Elisabeth, Hughes, Patrick M., Sarrazin, Christian, Boix, Michele
• Granted Patent: US 8,481,069 B2
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: Y10T 428/2985 Solid-walled microcapsule from synthetic polymer

Abstract

Biocompatible intraocular microspheres include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the microspheres can be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The microspheres can be placed into an eye to treat or reduce the occurrence of one or more ocular conditions.

Claims

1. A biodegradable intravitreal implant comprising:

a plurality of biodegradable polymer microspheres encapsulating a tyrosine kinase inhibitor (TKI), the microspheres releasing the TKI at a rate effective to sustain release of the TKI from the microspheres for at least about one week after the implant is placed in the vitreous of an eye.

2. The implant of claim 1, wherein the polymer is selected from the group consisting of polylactides, poly(lactide-co-glycolides), polycaprolactones, derivatives thereof, and mixtures thereof.

3. The implant of claim 1, wherein the microspheres release the TKI at a rate effective to sustain release of an amount of the TKI from the implant for more than one month from the time the implant is placed in the vitreous of the eye.

4. The implant of claim 1, wherein the tyrosine kinase inhibitor is provided in an amount from about 40% by weight to about 60% by weight of the implant, and the biodegradable polymer matrix comprises a poly(lactide-co-glycolide) in an amount from about 40% by weight to about 60% by weight of the implant.

5. A process for making biodegradable active agent microspheres, the process comprising the steps of:

(a) preparing an organic phase, which comprises, an active agent, a biodegradable polymer, and a solvent for the active agent and the polymer;

(b) preparing a first aqueous phase;

(c) combining the organic and the aqueous phase to form an emulsion;

(d) preparing a second aqueous phase;

(e) adding the second aqueous phase to the emulsion to form a solution

(f) stirring the solution, and;

(g) evaporating the solvent, thereby making biodegradable active agent microspheres.

6. The process of claim 5, wherein the organic phase is a viscous fluid.

7. The process of claim 5, further comprising the step of crystallizing active agent in the organic phase.

8. The process of claim 5, further comprising the step of crystallizing active agent in the emulsion.

9. The process of claim 5, wherein the pH of the first aqueous phase is between about pH 6 and about pH 8.

10. The process of claim 5, wherein the pH of the second aqueous phase is between about pH 4 and about pH 9.

12. Biodegradable active agent microspheres made by the process of claim 5.

11. A process for making biodegradable active agent microspheres, the process comprising the steps of:

(a) preparing a viscous organic phase, which comprises, a TKI, a biodegradable PLGA polymer, and a solvent for the active agent and the PLGA polymer;

(b) crystallizing active agent in the viscous organic phase

(c) preparing a first aqueous phase with a pH between about pH 6 and about pH 8;

(d) combining the organic and the aqueous phase to form an emulsion;

(e) crystallizing active agent in the emulsion;

(f) preparing a second aqueous phase with a pH between about pH 4 and about pH 9;

(g) adding the second aqueous phase to the emulsion to form a solution

(h) stirring the solution, and;

(i) evaporating the solvent, thereby making biodegradable active agent microspheres.

13. The process of claim 11, wherein the active agent is a TKI.

14. A method of treating an ocular condition of an eye of a patient, comprising the step of placing biodegradable intraocular microspheres into the vitreous of an eye of the patient, the microspheres comprising a TKI and a biodegradable polymer, wherein the microspheres degrades at a rate effective to sustain release of an amount of the TKI from the microspheres effective to treat the ocular condition.

15. The method of claim 14, wherein the method is effective to treat a retinal ocular condition.

16. The method of claim 14, wherein the ocular condition is glaucoma.

17. The method of claim 14, wherein the ocular condition is proliferative vitreoretinopathy.